Betaville Intelligence

RARE ALERT: GlaxoSmithKline said to ...

FTSE 100-listed GlaxoSmithKline, Switzerland-based Roche and Japan's Otsuka Pharmaceutical are all rumoured to be the large pharmaceutical companies involved in the strategic review being carried by Aurinia Pharmaceuticals, the US-listed rare disease drug developer.

People following the situation have heard speculation Goldman Sachs is advising Aurinia on the strategic review...


Register for free to see rest of this article and all public articles from Betaville

Login / Register
Date: Thursday, 28 October 2021, 3:04 pm

[Disclaimer - the information on Betaville does not consitute any form of investment recommendation and is not intended to be relied upon by readers in making, or refraining from, any investment decisions].

Login to join the conversation